8-K: Shattuck Labs Enters Collaboration Agreement with Ono Pharmaceutical for Novel Cancer Therapies

Shattuck Labs has partnered with Ono Pharmaceutical to research and develop bifunctional fusion proteins, potentially earning up to $226.5 million plus royalties.

Summary

• Shattuck Labs has entered into a collaboration and license agreement with Ono Pharmaceutical to jointly research and develop certain compounds.
• The agreement focuses on Shattuck's bifunctional fusion proteins, with Ono selecting the specific targets.
• Shattuck will conduct the research under a mutually agreed plan, overseen by a joint committee.
• Ono has an exclusive option to license the developed compounds for global commercialization.
• Shattuck is set to receive up to $9 million for initial payments and research milestones.
• If Ono exercises its option, Shattuck could receive up to $217.5 million in licensing, clinical, regulatory, and commercial milestone payments.
• Shattuck will also receive tiered royalties on global net sales, ranging from mid-single digits to low double digits, for up to ten years after the first commercial sale.
• Both companies are restricted from commercializing products with the same mechanism of action as the developed compounds during the agreement.
• The agreement can be terminated by mutual consent, breach, insolvency, or by Ono with 90 days' notice, with Ono covering Shattuck's costs up to termination.

Sentiment

Score: 8

Explanation: The document outlines a significant collaboration agreement with substantial potential financial benefits for Shattuck Labs, indicating a positive outlook. The deal structure is standard for the industry, and the potential for long-term revenue through royalties is promising.

Positives

• The collaboration provides Shattuck with significant upfront and milestone payments, totaling up to $226.5 million.
• Shattuck will receive tiered royalties on global net sales, potentially providing a long-term revenue stream.
• Ono will cover all of Shattuck's research costs, reducing Shattuck's financial burden.
• The partnership validates Shattuck's technology and pipeline.
• The agreement provides Shattuck with a potential path to commercialization through a major pharmaceutical partner.

Negatives

• Shattuck is restricted from commercializing products with the same mechanism of action as the developed compounds during the agreement.
• Ono can terminate the agreement with 90 days' notice, potentially disrupting Shattuck's plans.
• The full potential of the agreement is contingent on Ono exercising its option and successfully commercializing the products.

Risks

• The success of the collaboration depends on the successful research and development of the compounds.
• Ono may not exercise its option, limiting Shattuck's potential revenue.
• The development and commercialization of new drugs is subject to regulatory and clinical risks.
• The agreement could be terminated due to breach, insolvency, or Ono's decision to discontinue development.

Future Outlook

The collaboration agreement sets the stage for potential future revenue streams for Shattuck Labs through milestone payments and royalties, contingent on the successful development and commercialization of the compounds by Ono Pharmaceutical.

Management Comments

• Dr. Taylor Schreiber, Chief Executive Officer of Shattuck Labs, signed the report on behalf of the company.

Industry Context

This collaboration reflects a growing trend in the pharmaceutical industry where companies partner to leverage each other's expertise and resources in developing novel therapies, particularly in the field of oncology. It also highlights the increasing interest in bifunctional fusion proteins as a promising therapeutic modality.

Comparison to Industry Standards

• The structure of this deal, with upfront payments, milestone payments, and royalties, is typical for pharmaceutical collaborations.
• Similar deals in the oncology space often involve significant upfront payments and potential milestone payments exceeding $100 million, which this deal aligns with.
• The royalty rates, ranging from mid-single digits to low double digits, are also within the typical range for such agreements.
• Companies like Xencor and MacroGenics have similar technology platforms and have entered into comparable collaboration agreements with larger pharmaceutical companies.

Stakeholder Impact

• Shareholders may view this collaboration positively due to the potential for future revenue and growth.
• Employees may benefit from the increased research activity and potential for career advancement.
• Customers (patients) may benefit from the development of new therapies.
• Suppliers may see increased demand for research-related materials and services.
• Creditors may view the company as more financially stable due to the potential for future revenue.

Next Steps

• Shattuck Labs will conduct research activities according to the mutually agreed upon research plan.
• Shattuck Labs will deliver a final report pursuant to the Research Plan.
• Ono will decide whether to exercise its option to license the developed compounds.
• Shattuck Labs intends to file the Collaboration Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

Key Dates

Keywords

Collaboration Agreement, Bifunctional Fusion Proteins, Ono Pharmaceutical, Shattuck Labs, Licensing Agreement, Milestone Payments, Royalties, Research and Development, Cancer Therapies